Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
immune checkpoint inhibitors
immunotherapy
immunotherapy resistance
metastatic prostate cancer
tumor microenvironment
tumor-associated macrophages
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Jan 2022
16 Jan 2022
Historique:
received:
23
12
2021
revised:
13
01
2022
accepted:
15
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Prostate cancer (PC) is the most common malignancy and the fifth cause of cancer death in men. The treatment for localized or locally advanced stages offers a high probability of cure. Even though the therapeutic landscape has significantly improved over the last decade, metastatic PC (mPC) still has a poor prognosis mainly due to the development of therapy resistance. In this context, the use of immunotherapy alone or in combination with other drugs has been explored in recent years. However, T-cell directed immune checkpoint inhibitors (ICIs) have shown limited activity with inconclusive results in mPC patients, most likely due to the highly immunosuppressive PC tumor microenvironment (TME). In this scenario, targeting macrophages, a highly abundant immunosuppressive cell type in the TME, could offer a new therapeutic strategy to improve immunotherapy efficacy. In this review, we summarize the growing field of macrophage-directed immunotherapies and discuss how these could be applied in the treatment of mPC, focusing on their combination with ICIs.
Identifiants
pubmed: 35053602
pii: cancers14020440
doi: 10.3390/cancers14020440
pmc: PMC8773572
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Agency for Administration of University and Research
ID : 2019 PROD 00118, 2017-SGR-490
Organisme : La Caixa Foundation
ID : CI20-00152
Organisme : Instituto de Salud Carlos III
ID : PFIS (FI20/00115)
Organisme : Health Department of Catalan Government
ID : CERCA network
Organisme : Juan de la Cierva
ID : FJC2019-041213-I
Références
Nat Rev Cancer. 2012 Mar 01;12(4):307-13
pubmed: 22378190
JAMA Oncol. 2016 Apr;2(4):493-9
pubmed: 26794729
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
Clin Cancer Res. 2013 Dec 15;19(24):6891-901
pubmed: 24255071
Cancer Chemother Pharmacol. 2014 Jan;73(1):1-8
pubmed: 24162378
Oncotarget. 2017 Jun 13;8(24):39021-39032
pubmed: 28380460
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
pubmed: 12359855
Cochrane Database Syst Rev. 2020 Dec 3;12:CD013020
pubmed: 33270906
J Clin Oncol. 2008 Jan 10;26(2):242-5
pubmed: 18182665
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Am J Pathol. 2015 Oct;185(10):2596-606
pubmed: 26118749
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
Br J Cancer. 2014 Aug 12;111(4):646-50
pubmed: 24755886
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Clin Cancer Res. 2019 Mar 1;25(5):1564-1573
pubmed: 30442684
Oncotarget. 2016 Jul 5;7(27):41662-41676
pubmed: 27191500
Oncol Res. 2017 Nov 2;25(9):1579-1587
pubmed: 28337964
Cell Death Dis. 2019 Aug 8;10(8):598
pubmed: 31395859
J Natl Cancer Inst. 1995 Feb 15;87(4):280-5
pubmed: 7707419
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
Eur J Cancer. 2012 Oct;48(15):2361-8
pubmed: 22541893
J Leukoc Biol. 2017 Sep;102(3):657-675
pubmed: 28606940
Cancer Immunol Immunother. 2014 Nov;63(11):1177-87
pubmed: 25085000
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Oncoimmunology. 2015 Dec 10;5(3):e1089381
pubmed: 27141346
J Immunol Res. 2018 Nov 7;2018:6156757
pubmed: 30525058
Oncotarget. 2016 Apr 26;7(17):23909-18
pubmed: 26992207
Eur Urol. 2019 Mar;75(3):378-382
pubmed: 30337059
Cancer Res Treat. 2015 Apr;47(2):306-12
pubmed: 25483747
EMBO J. 1991 Feb;10(2):277-88
pubmed: 1825054
Transpl Immunol. 2022 Feb;70:101512
pubmed: 34871717
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
Prostate. 2017 Mar;77(4):385-395
pubmed: 27862097
Sci Rep. 2016 Jul 14;6:29719
pubmed: 27411490
Lancet. 2021 Sep 18;398(10305):1075-1090
pubmed: 34370973
Cancer Lett. 2007 Nov 8;257(1):16-35
pubmed: 17697748
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Cochrane Database Syst Rev. 2017 Dec 26;12:CD006250
pubmed: 29278410
Int J Mol Sci. 2019 Apr 13;20(8):
pubmed: 31013891
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
Lancet Oncol. 2019 Oct;20(10):1432-1443
pubmed: 31515154
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
J Immunother Cancer. 2015 Dec 15;3:53
pubmed: 26673090
Oncogene. 2010 Mar 4;29(9):1293-302
pubmed: 19946339
Front Endocrinol (Lausanne). 2018 Jun 21;9:314
pubmed: 29977225
J Cell Biol. 2007 Dec 17;179(6):1275-87
pubmed: 18070912
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
J Leukoc Biol. 2017 Aug;102(2):393-406
pubmed: 28550116
Signal Transduct Target Ther. 2021 Mar 26;6(1):127
pubmed: 33767177
Cell Prolif. 2021 Oct;54(10):e13115
pubmed: 34464477
Mol Cancer Ther. 2011 Nov;10(11):2135-45
pubmed: 21903606
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncotarget. 2017 Feb 7;8(6):9739-9751
pubmed: 28039457
Nature. 1998 Apr 9;392(6676):565-8
pubmed: 9560152
Respir Res. 2018 Jan 05;19(1):3
pubmed: 29304863
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8389-8401
pubmed: 31966691
Cancer Res. 2007 Jul 15;67(14):6549-54
pubmed: 17638863
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Nat Med. 2016 Aug;22(8):851-60
pubmed: 27376576
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690-5
pubmed: 16407111
Elife. 2018 Jun 04;7:
pubmed: 29862966
Sci Rep. 2015 Oct 27;5:15651
pubmed: 26503803
Blood Adv. 2019 Feb 26;3(4):531-540
pubmed: 30770362
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
Ann Nucl Med. 2018 Oct;32(8):553-560
pubmed: 30094545
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Front Immunol. 2019 Mar 28;10:603
pubmed: 30984182
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946818
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Invest New Drugs. 2021 Oct;39(5):1284-1297
pubmed: 33852104
Cancer Lett. 2018 Nov 28;437:25-34
pubmed: 30165193
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Cytokine. 2015 Oct;75(2):261-71
pubmed: 26113402
Oncogene. 2021 Jan;40(2):396-407
pubmed: 33159168
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Int J Mol Sci. 2012;13(8):9545-71
pubmed: 22949815
Sci Rep. 2019 Feb 28;9(1):3172
pubmed: 30816272
Am J Pathol. 2011 Oct;179(4):2100-7
pubmed: 21854753
Cell Death Dis. 2020 Apr 16;11(4):234
pubmed: 32300100
J Cancer Res Clin Oncol. 2018 Sep;144(9):1751-1768
pubmed: 29797220
FASEB J. 2020 Jul;34(7):9405-9418
pubmed: 32453916
Cancers (Basel). 2021 Oct 28;13(21):
pubmed: 34771578
Lancet. 2019 Aug 10;394(10197):478-487
pubmed: 31229240
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
J Clin Invest. 2012 Sep;122(9):3127-44
pubmed: 22922255
J Immunol. 2005 Feb 15;174(4):2004-11
pubmed: 15699129
Clin Cancer Res. 2017 Dec 15;23(24):7448-7453
pubmed: 28774898
J Biol Chem. 2012 Apr 20;287(17):13694-704
pubmed: 22375015
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
Ann Oncol. 2012 May;23(5):1234-1240
pubmed: 21930687
Front Oncol. 2021 Jan 05;10:615534
pubmed: 33469516
Clin Cancer Res. 2017 Nov 15;23(22):6764-6770
pubmed: 28663235
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Cancer Lett. 2021 Dec 28;523:162-169
pubmed: 34517086
Bone. 2021 Jun;147:115907
pubmed: 33676057
Oncotarget. 2014 Mar 30;5(6):1595-608
pubmed: 24721786
Med Klin (Munich). 1988 May 27;83(12):398-401
pubmed: 3043159
Pharmacol Ther. 2016 Feb;158:24-40
pubmed: 26617219
Ann Oncol. 2017 Nov 1;28(11):2741-2746
pubmed: 29059273
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34599024
Nat Commun. 2020 Sep 9;11(1):4498
pubmed: 32908142
Anticancer Res. 2015 Feb;35(2):865-74
pubmed: 25667468
Br J Cancer. 2017 Nov 21;117(11):1631-1643
pubmed: 28949956
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Clin Oncol. 2011 Oct 20;29(30):4022-8
pubmed: 21931019
Cancer Res. 2012 Jan 15;72(2):430-9
pubmed: 22108823
Ther Adv Urol. 2016 Feb;8(1):9-18
pubmed: 26834836
Trends Cell Biol. 2001 Mar;11(3):130-5
pubmed: 11306274
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Immunol. 2005 Jul 1;175(1):342-9
pubmed: 15972667
JAMA Oncol. 2019 Apr 1;5(4):471-478
pubmed: 30589920
Nat Rev Cancer. 2014 Sep;14(9):598-610
pubmed: 25098269
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122
pubmed: 28096371
Clin Cancer Res. 2020 Oct 1;26(19):5162-5171
pubmed: 32513836
J Cell Sci. 2011 Jun 15;124(Pt 12):2021-31
pubmed: 21610095
Medicine (Baltimore). 2016 Mar;95(9):e2675
pubmed: 26945355
Nat Commun. 2017 Feb 08;8:14293
pubmed: 28176769
J Clin Invest. 2006 Jul;116(7):1935-45
pubmed: 16778987
Cancer Immunol Res. 2015 Feb;3(2):136-48
pubmed: 25370534
BJU Int. 2011 Jun;107(12):1918-22
pubmed: 21044246
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31611249
JCI Insight. 2018 Jun 7;3(11):
pubmed: 29875321
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
Biomed Res Int. 2018 Jul 30;2018:2124390
pubmed: 30151375
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
BMC Biol. 2017 Jun 29;15(1):53
pubmed: 28662662
Prostate. 2019 Mar;79(4):363-369
pubmed: 30500076
Cancer Lett. 2015 May 1;360(2):302-9
pubmed: 25721088
Mol Cancer. 2020 Feb 27;19(1):41
pubmed: 32103760
J Clin Invest. 2016 Jul 1;126(7):2610-20
pubmed: 27294525
J Transl Med. 2011 Oct 17;9:177
pubmed: 22005011
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34
pubmed: 19202079
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Mol Cancer. 2021 Apr 4;20(1):62
pubmed: 33814009
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Drug Resist Updat. 2012 Feb-Apr;15(1-2):39-49
pubmed: 22335920
World J Gastroenterol. 2012 Jun 21;18(23):2938-47
pubmed: 22736917
J Clin Oncol. 2016 Aug 1;34(22):2636-43
pubmed: 27298414
Cancer Discov. 2012 Aug;2(8):706-21
pubmed: 22609699
EMBO Mol Med. 2013 Sep;5(9):1383-401
pubmed: 23982944
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546897
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Oncotarget. 2018 Jun 15;9(46):28226-28239
pubmed: 29963274
Eur Urol Focus. 2019 Mar;5(2):147-154
pubmed: 30772358
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5689-94
pubmed: 23493555
Immunotherapy. 2017 Mar;9(4):347-360
pubmed: 28303764
Oncol Lett. 2015 Sep;10(3):1390-1396
pubmed: 26622679
Clin Cancer Res. 2020 Nov 1;26(21):5609-5620
pubmed: 32847933
Cancer Res. 2015 Mar 15;75(6):950-62
pubmed: 25736687
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5434-43
pubmed: 27578867
Cancer Lett. 2021 Oct 28;519:20-29
pubmed: 34153403
Cell. 2015 Sep 24;163(1):160-73
pubmed: 26406376
Clin Exp Metastasis. 2019 Jun;36(3):199-209
pubmed: 30963355
Cell. 2013 Jan 31;152(3):467-78
pubmed: 23374343
Front Immunol. 2019 Aug 09;10:1893
pubmed: 31447860
Cancer Res. 2013 May 1;73(9):2782-94
pubmed: 23418320
Cell. 2009 Jul 23;138(2):271-85
pubmed: 19632178
Clin Cancer Res. 1999 Jul;5(7):1738-44
pubmed: 10430077
Clin Cancer Res. 2011 Jun 1;17(11):3520-6
pubmed: 21471425
Cell Rep. 2019 Aug 20;28(8):2156-2168.e5
pubmed: 31433989
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2019 Dec 20;37(36):3507-3517
pubmed: 31644357
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23
pubmed: 26512116
J Clin Oncol. 2014 Apr 10;32(11):1143-50
pubmed: 24590644
Cancers (Basel). 2020 Jul 13;12(7):
pubmed: 32668821